CAS: 19879-30-2; (S)-2-(4-Hydroxyphenyl)-7-Methoxy-6-(3-Methylbut-2-En-1-yl)Chroman-4-One

上下游产品

(E)-1-(2-hydroxy-4-methoxy-5-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one 7-methoxy-2-(4-(methoxymethoxy)phenyl)-6-(3-methylbut-2-en-1-yl)chroman-4-one 1-(2-hydroxy-4-methoxyphenyl)ethanone 4-methoxymethoxy-benzaldehyde

📜Bavachinin置于chiralpak Oz-H Column体系中,用 乙醇 用作溶剂,40.0 °C,10.0 Mpa 条件下,反应生成(R)-Bavachinin,甲基补骨脂黄酮a
参考文献:Separation And Peroxisome Proliferator-Activated Receptor-γ Agonist Activity Evaluation Of Synthetic Racemic Bavachinin Enantiomers
标题:Separation And Peroxisome Proliferator-Activated Receptor-γ Agonist Activity Evaluation Of Synthetic Racemic Bavachinin Enantiomers
摘要:Bavachinin,Isolated From Psoralea Corylifolia Seeds,Has Been Reported To Demonstrate Peroxisome Proliferator-Activated Receptor-Gamma (Ppar-Gamma) Agonist Activity. However,Isolated Bavachinin Is Actually A Mixture Of S And R Configurations,With An Enantiomeric Excess Value Of Approximately 24.3%. For Further Study On The Structure-Activity Relationships Of Bavachinin,Investigating The Ppar-Gamma Agonist Activity Of The Two Enantiomers Is Crucial. Considering The Limited Availability,Racemic Bavachinin Was Prepared In This Study Using Chemical Synthesis. The Enantiomers Of Racemic Bavachinin Were Then Separated Using Supercritical Fluid Chromatography. This Concise Strategy Yielded (S)-And (R)-Bavachinin In Optical Purity As High As >= 97.5%. The Ppar-Gamma Agonist Activity Of The Two Enantiomers Was Evaluated Using A Time-Resolved Fluorescence Resonance Energy Transfer-Based Competitive Binding Assay Method; Ic50 Values Of (S)-And (R)-Bavachinin Were 616.7 And 471.2 Nm,Respectively. The Interaction Between The Compounds And Ppar-Gamma Was Further Explored Using A Molecular Docking Method. This Study Suggests That (S)-And (R)-Bavachinin Demonstrate Similar Ppar-Gamma Agonist Activities. (C) 2015 Elsevier Ltd. All Rights Reserved.
Doi:10.1016/j.Bmcl.2015.04.029

专利信息

专利号:WO-2024108105-A1
优先权日:2022-11-17
标题 :Compositions and methods for enhancing car-t cell performance and for cancer immunotherapy
发明人：GOLDRATH ANANDA; REINA-CAMPOS MIGUEL; GALLETTI GIOVANNI
权利人:UNIV CALIFORNIA
摘要:Provided are methods for metabolically enhancing CAR-T cell function in vitro and in vivo , and their persistence in vivo , wherein the enhancing of CAR-T cells can be used for the enhancement of CAR-T cell efficacy in cancer immunotherapy. Provided herein are methods for enhancing the ability of chimeric antigen receptor (CAR)-CD8 T cells to persist longer in solid tumors by inhibiting a squalene synthase (or Fdft1), an enzyme of the mevalonate/cholesterol synthesis pathway. In alternative embodiments, provided herein are CAR-T cells that have been treated in vivo or ex vivo with an agent, to delete or diminish the activity of a squalene synthase in the CAR-T cell. Provided herein are methods for treating a cancer comprising administration of an agent, which for example can be an inhibitory nucleic acid or a small molecule inhibitor, to delete or diminish the activity of a squalene synthase in the cancer cell.

专利号:CN-103724309-A
优先权日:2013-12-23
标 题 :A kind of psoralen dihydroflavone methyl ether hydroxylated derivative and its synthesis method

专利号:CN-103724309-B
优先权日:2013-12-23
标 题 :A kind of psoralen dihydroflavone methyl ether hydroxylated derivative and its synthesis method